Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1669.4 Billion KRW | 12.17% |
| 2022 | 1488.34 Billion KRW | 10.78% |
| 2021 | 1343.55 Billion KRW | 3.11% |
| 2020 | 1303 Billion KRW | 20.72% |
| 2019 | 1079.33 Billion KRW | 12.88% |
| 2018 | 956.21 Billion KRW | 8.13% |
| 2017 | 884.36 Billion KRW | 6.3% |
| 2016 | 831.98 Billion KRW | 40.42% |
| 2015 | 592.49 Billion KRW | 8.89% |
| 2014 | 544.12 Billion KRW | 530.38% |
| 2013 | 86.31 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 396.8 Billion KRW | 12.27% |
| 2024 Q1 | 353.45 Billion KRW | -29.96% |
| 2023 Q3 | 403.6 Billion KRW | 1.92% |
| 2023 Q4 | 504.61 Billion KRW | 25.03% |
| 2023 FY | 1669.4 Billion KRW | 12.17% |
| 2023 Q1 | 365.18 Billion KRW | -8.03% |
| 2023 Q2 | 396 Billion KRW | 8.44% |
| 2022 Q3 | 383.88 Billion KRW | 4.88% |
| 2022 Q2 | 366.02 Billion KRW | 7.22% |
| 2022 Q1 | 341.37 Billion KRW | -5.66% |
| 2022 FY | 1488.34 Billion KRW | 10.78% |
| 2022 Q4 | 397.05 Billion KRW | 3.43% |
| 2021 Q1 | 311.91 Billion KRW | -7.51% |
| 2021 Q2 | 327.53 Billion KRW | 5.01% |
| 2021 Q3 | 342.23 Billion KRW | 4.49% |
| 2021 Q4 | 361.87 Billion KRW | 5.74% |
| 2021 FY | 1343.55 Billion KRW | 3.11% |
| 2020 Q1 | 293.36 Billion KRW | -1.62% |
| 2020 Q3 | 358.39 Billion KRW | 14.13% |
| 2020 Q4 | 337.22 Billion KRW | -5.91% |
| 2020 Q2 | 314.02 Billion KRW | 7.04% |
| 2020 FY | 1303 Billion KRW | 20.72% |
| 2019 Q2 | 266.56 Billion KRW | 13.91% |
| 2019 FY | 1079.33 Billion KRW | 12.88% |
| 2019 Q4 | 298.18 Billion KRW | 6.27% |
| 2019 Q3 | 280.58 Billion KRW | 5.26% |
| 2019 Q1 | 234 Billion KRW | -11.77% |
| 2018 Q3 | 235.1 Billion KRW | -0.94% |
| 2018 Q4 | 265.23 Billion KRW | 12.82% |
| 2018 FY | 956.21 Billion KRW | 8.13% |
| 2018 Q2 | 237.33 Billion KRW | 8.6% |
| 2018 Q1 | 218.54 Billion KRW | -10.43% |
| 2017 Q1 | 209.69 Billion KRW | 0.0% |
| 2017 FY | 884.36 Billion KRW | 6.3% |
| 2017 Q2 | 211 Billion KRW | 0.62% |
| 2017 Q3 | 219.65 Billion KRW | 4.1% |
| 2017 Q4 | 243.99 Billion KRW | 11.08% |
| 2016 Q1 | 201.94 Billion KRW | 29.88% |
| 2016 Q2 | 205.68 Billion KRW | 1.85% |
| 2016 Q3 | 204.67 Billion KRW | -0.49% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | 831.98 Billion KRW | 40.42% |
| 2015 FY | 592.49 Billion KRW | 8.89% |
| 2015 Q4 | 155.49 Billion KRW | 3.88% |
| 2015 Q3 | 149.68 Billion KRW | 6.9% |
| 2015 Q2 | 140.02 Billion KRW | -4.93% |
| 2015 Q1 | 147.29 Billion KRW | 4.31% |
| 2014 Q1 | 138.68 Billion KRW | 0.0% |
| 2014 FY | 544.12 Billion KRW | 530.38% |
| 2014 Q2 | 136.95 Billion KRW | -1.25% |
| 2014 Q3 | 127.28 Billion KRW | -7.06% |
| 2014 Q4 | 141.21 Billion KRW | 10.94% |
| 2013 FY | 86.31 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1116.682% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | -47.474% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -161.479% |
| HANDOK Inc. | 522.74 Billion KRW | -219.356% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -1133.191% |
| Yuhan Corporation | 1858.98 Billion KRW | 10.198% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -151.424% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -3113.171% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | -11.974% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -1137.422% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -350.536% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -1784.34% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -884.508% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -643.753% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1116.682% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -2038.802% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -1005.045% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -1810.869% |
| JW Holdings Corporation | 928.07 Billion KRW | -79.879% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -177.883% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -123.025% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -733.749% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -823.534% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -750.237% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -129.821% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1116.682% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | -10.231% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | -21.382% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -123.025% |
| Yuhan Corporation | 1858.98 Billion KRW | 10.198% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -110.064% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -610.68% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -180.776% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -123.025% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -471.462% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -498.474% |
| CKD Bio Corp. | 160.35 Billion KRW | -941.082% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -216.804% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -362.3% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -624.588% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -733.749% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -89.752% |
| Boryung Corporation | 859.62 Billion KRW | -94.201% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -1225.679% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -350.536% |
| JW Lifescience Corporation | 206.86 Billion KRW | -707.02% |